# ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
Canonical URL: https://biopharmsignal.com/news/PROK/prokidney-reports-first-quarter-2026-financial-results-and-business-highlights
Ticker: PROK
Company: ProKidney
Source: ProKidney
Published: 2026-05-15 15:45 EST
Original Source URL: https://investors.prokidney.com
## Summary

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology

## Article Body
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology
## Recent Company News
- 2026-06-02 12:00 EST — [ProKidney Appoints Kenneth Locke as Chief Technical Officer](https://biopharmsignal.com/news/PROK/prokidney-appoints-kenneth-locke-as-chief-technical-officer) — Source: ProKidney
- 2026-05-15 15:45 EST — [ProKidney Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-first-quarter-2026-financial-results-and-business-highlights) — Source: ProKidney
- 2026-03-25 20:01 EST — [ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer](https://biopharmsignal.com/news/PROK/prokidney-expands-senior-leadership-team-with-appointment-of-greg-madison-as-chief-commercial-officer) — Source: ProKidney
- 2026-03-18 20:00 EST — [ProKidney Reports Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-full-year-2025-financial-results-and-business-highlights) — Source: ProKidney
- 2026-01-06 12:30 EST — [ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/PROK/prokidney-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference) — Source: ProKidney
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)